• Explore /
  • Poster
  • / Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.

Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.

Abstract Poster

Authors

null

Sant P. Chawla

Sarcoma Oncology Research Center, Santa Monica, CA

Sant P. Chawla, Victoria S. Chua, Erlinda Maria Gordon, Ania Moradkhani, Katherine Kim, Doris Quon, Steven Wong, Robert Sumner, Virginia Mac, Raymond Huang, Kelly Wang, Jiyeun Kim, Bumjin Kim, Arlo N. McGinn, Cheol Hee Park, Scott Houston, Neil Sankar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT03396211

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr 18)

DOI

10.1200/JCO.2019.37.8_suppl.18

Abstract #

18

Poster Bd #

B2

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Gastrointestinal Cancers Symposium

A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.

First Author: Makoto Ueno

First Author: Igor Tsaur

First Author: Ilya Tsimafeyeu

First Author: Kazuto Nakamura